Patents by Inventor Yoshiaki Isobe

Yoshiaki Isobe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210363810
    Abstract: Disclosed is a vehicular opening/closing body control device including: a positional information acquisition; a storage part; and a motor control part. The motor control part includes: a drive start part that operates the motor based on the positional information so that the opening/closing body in a stopped state is moved; and a drive part that performs feedback control of the motor based on the positional information and the target value so that the movement speed of the opening/closing body which has been started to move by the drive start part reaches the target value. The drive start part generates a first output in the motor when the opening/closing body is at a first position, and generates a second output smaller that the first output in the motor when the opening/closing body is at a second position closer to a fully closed position than the first position.
    Type: Application
    Filed: April 12, 2019
    Publication date: November 25, 2021
    Applicant: MITSUBA Corporation
    Inventor: Yoshiaki ISOBE
  • Publication number: 20210198242
    Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.
    Type: Application
    Filed: October 26, 2020
    Publication date: July 1, 2021
    Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
  • Publication number: 20210173938
    Abstract: A system performs an application update process based on security management information that is information including meta information for each of a plurality of security services. The application update process is a process for adding one or more security services including a security service that reduces the security risk of an application having a plurality of distributed microservices having a graph structure relationship to the application.
    Type: Application
    Filed: September 23, 2020
    Publication date: June 10, 2021
    Inventors: Jens DOENHOFF, Nodoka MIMURA, Yoshiaki ISOBE
  • Publication number: 20210029153
    Abstract: A threat analysis system includes a storage unit that stores first information in which a device configuring a threat analysis target system and a vulnerability included in the device are associated with each other, and second information in which the device and a threat from a viewpoint of a business operator assumed in the threat analysis target system are associated with each other; a threat analysis processing unit that associates the vulnerability included in the device and a threat in the threat analysis target system with each other on a basis of the first information and the second information stored in the storage unit; and a threat-analysis result output unit that outputs a relationship between the vulnerability and the threat associated by the threat analysis processing unit.
    Type: Application
    Filed: February 22, 2019
    Publication date: January 28, 2021
    Inventors: Akihiro SUGIMOTO, Yoshiaki ISOBE
  • Publication number: 20210008197
    Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.
    Type: Application
    Filed: March 18, 2020
    Publication date: January 14, 2021
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hidenori Kimura, Hitoshi Ban, Yoshiaki Isobe, Hitoshi Watanabe
  • Patent number: 10870642
    Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: December 22, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
  • Patent number: 10703755
    Abstract: The present invention relates to a substituted purine derivative of formula (1) wherein R1 is alkoxy or the like, R2 is alkyl or the like, Ring Q1 is aryl or the like, W1 is alkylene or the like, Ring Q2 is aromatic carbocyclyl or the like, n is 1-4, R3 is hydrogen atom or the like, X1 is single bond or the like, W2 is alkylene or the like, and R4 is hydrogen atom or the like, or a pharmaceutically acceptable salt thereof, which has a potent inhibitory effect against TLR7, and thereby is useful for treating autoimmune disease.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: July 7, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Shingo Tojo, Yoshiaki Isobe, Eiji Ideue, Hiroaki Fujiwara, Daisuke Urabe
  • Patent number: 10632192
    Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: April 28, 2020
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hidenori Kimura, Hitoshi Ban, Yoshiaki Isobe, Hitoshi Watanabe
  • Publication number: 20190308958
    Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.
    Type: Application
    Filed: April 24, 2019
    Publication date: October 10, 2019
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
  • Patent number: 10323024
    Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: June 18, 2019
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
  • Publication number: 20190169191
    Abstract: The present invention relates to a substituted purine derivative of formula (1) wherein R1 is alkoxy or the like, R2 is alkyl or the like, Ring Q1 is aryl or the like, W1 is alkylene or the like, Ring Q2 is aromatic carbocyclyl or the like, n is 1-4, R3 is hydrogen atom or the like, X1 is single bond or the like, W2 is alkylene or the like, and R4 is hydrogen atom or the like, or a pharmaceutically acceptable salt thereof, which has a potent inhibitory effect against TLR7, and thereby is useful for treating autoimmune disease.
    Type: Application
    Filed: April 25, 2017
    Publication date: June 6, 2019
    Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Shingo TOJO, Yoshiaki ISOBE, Eiji IDEUE, Hiroaki FUJIWARA, Daisuke URABE
  • Publication number: 20190016711
    Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.
    Type: Application
    Filed: January 12, 2017
    Publication date: January 17, 2019
    Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi WATANABE, Yoshiaki ISOBE, Hidenori KIMURA, Yuji FUJIWARA
  • Publication number: 20180280499
    Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.
    Type: Application
    Filed: October 6, 2016
    Publication date: October 4, 2018
    Inventors: Hidenori Kimura, Hitoshi Ban, Yoshiaki Isobe, Hitoshi Watanabe
  • Patent number: 9479330
    Abstract: With a portal server, a request for information from a terminal of a second user that is an agent for a first user is received, and an encrypted data directed to a terminal of the first user, stored in an encrypted-data memory unit, is re-encrypted using a re-encryption key for the second user, stored in a first encryption-key memory unit, and is transmitted to the terminal of the second user, with the terminal of the second user, the re-encrypted data received is decrypted using an encryption key for the second user, stored in a second encryption-key memory unit, and time keys specified by the terminal of the first user, related to a time-period during which browsing of the information is permitted.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: October 25, 2016
    Assignee: Hitachi, Ltd.
    Inventors: Kosuke Anzai, Hisayoshi Sato, Yoshiaki Isobe, Suguru Iwasaki
  • Patent number: 9419804
    Abstract: A data authenticity assurance method carried out by a management computer including: a first step of receiving the first data piece from the computer; a second step of selecting a plurality of second data pieces at predetermined intervals in chronological order from among the plurality of second data pieces held in the data holding part; a third step of performing an arithmetic operation for each of the hash values of the selected plurality of second data pieces; a fourth step of generating signature target data by combining the first data piece received from the computer with the hash values of the selected plurality of second data pieces; and a fifth step of generating a second data piece by assigning the digital signature to the signature target data by using the preset key, and holding the generated second data piece in chronological order sequentially in the data holding part.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: August 16, 2016
    Assignee: HITACHI, LTD.
    Inventors: Natsuki Watanabe, Yoko Hashimoto, Kosuke Anzai, Kunihiko Miyazaki, Naoki Hayashi, Yoshiaki Isobe, Tomohisa Kumagai, Daisuke Miyamoto
  • Publication number: 20150082040
    Abstract: With a portal server, a request for information from a terminal of a second user that is an agent for a first user is received, and an encrypted data directed to a terminal of the first user, stored in an encrypted-data memory unit, is re-encrypted using a re-encryption key for the second user, stored in a first encryption-key memory unit, arid is transmitted to the terminal of the second user, with the terminal of the second user, the re-encrypted data received is decrypted using an encryption key for the second user, stored in a second encryption-key memory unit, and time keys specified by the terminal of the first user, related to a time-period during which browsing of the information is permitted.
    Type: Application
    Filed: June 13, 2014
    Publication date: March 19, 2015
    Applicant: Hitachi, Ltd.
    Inventors: KOSUKE ANZAI, Hisayoshi Sato, Yoshiaki Isobe, Suguru Iwasaki
  • Patent number: 8969362
    Abstract: The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: March 3, 2015
    Assignees: AstraZeneca Aktiebolag, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Ayumu Kurimoto, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
  • Publication number: 20140298034
    Abstract: A data authenticity assurance method carried out by a management computer including: a first step of receiving the first data piece from the computer; a second step of selecting a plurality of second data pieces at predetermined intervals in chronological order from among the plurality of second data pieces held in the data holding part; a third step of performing an arithmetic operation for each of the hash values of the selected plurality of second data pieces; a fourth step of generating signature target data by combining the first data piece received from the computer with the hash values of the selected plurality of second data pieces; and a fifth step of generating a second data piece by assigning the digital signature to the signature target data by using the preset key, and holding the generated second data piece in chronological order sequentially in the data holding part.
    Type: Application
    Filed: October 2, 2012
    Publication date: October 2, 2014
    Applicant: Hitachi, Ltd.
    Inventors: Natsuki Watanabe, Yoko Hashimoto, Kosuke Anzai, Kunihiko Miyazaki, Naoki Hayashi, Yoshiaki Isobe, Tomohisa Kumagai, Daisuke Miyamoto
  • Publication number: 20140045837
    Abstract: The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 13, 2014
    Applicants: AstraZeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Ayumu Kurimoto, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
  • Patent number: 8575180
    Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: November 5, 2013
    Assignees: AstraZeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Ayumu Kurimoto, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally